Welcome to our dedicated page for Metsera SEC filings (Ticker: MTSR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Metsera's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Metsera's regulatory disclosures and financial reporting.
Metsera, Inc. (MTSR) received an amended Schedule 13G showing Janus Henderson Group plc as a passive institutional holder. Janus Henderson and its affiliated asset managers are deemed to beneficially own 3,242,849 shares of Metsera common stock, representing 3.1% of the class as of 12/31/2025.
All voting and investment power over these shares is shared through various asset management subsidiaries that manage client accounts, referred to as Managed Portfolios. The Managed Portfolios, not Janus Henderson, have the right to receive dividends and sale proceeds, and none of them individually owns more than five percent of Metsera’s common stock.
Janus Henderson certifies that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Metsera, consistent with a passive investment stance.
Metsera, Inc. reported insider changes tied to its merger with Pfizer Inc., where all reported Metsera common shares were converted into cash and contingent value rights. The filing shows that indirect holdings reported through F-Prime Inc. and other related persons and entities went to zero following transactions dated 11/13/2025. Under the merger agreement among Metsera, Pfizer and Mayfair Merger Sub, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, net of applicable withholding taxes, plus one contractual contingent value right providing for potential additional cash payments if specified milestones are achieved.
Metsera, Inc. (MTSR) reported insider transactions tied to its merger with Pfizer. On 11/13/2025, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR) under the merger terms.
The Chief Medical Officer reported disposition of 17,000 common shares, leaving 0 shares beneficially owned. Outstanding stock options were canceled for cash based on the $65.60 closing amount and CVRs per share covered, including options over 120,000 shares (exercise price $29.25) and options over 829,885 and 21,279 shares (exercise price $0.26). RSUs were also canceled and converted into cash based on the closing amount and an equivalent number of CVRs, with vesting terms preserved under the agreement.
Metsera (MTSR) filed a Form 4 tied to its merger with Pfizer. The filing states each Metsera common share was converted into $65.60 in cash plus one contingent value right (CVR) at closing. The reporting director recorded merger-related dispositions of common stock and the cancellation of equity awards in exchange for the cash consideration and CVRs.
On 11/13/2025, outstanding stock options were canceled for cash (based on the $65.60 closing amount minus the exercise price) and CVRs; RSUs were canceled for cash at $65.60 per underlying share and CVRs. The table shows 4,031 RSUs, and stock options covering 24,188 and 223,430 shares, all settled, with reported post‑transaction holdings shown as zero in the listed entries.
Metsera, Inc. (MTSR) filed a Form 4 for its Chief Legal Officer detailing equity conversions arising from the closing of its merger with Pfizer. At the effective time, each common share converted into $65.60 in cash per share plus one contingent value right (CVR) tied to specified milestones.
The filing reports the disposition of 12,500 shares of common stock, leaving 0 shares beneficially owned. It also shows 12,500 RSUs subject to conversion into cash at the $65.60 closing amount per underlying share plus CVRs, following their original vesting schedule. In addition, stock options for 46,875 shares (exercise price $29.25) and 325,000 shares (exercise price $17.16) were canceled and exchanged for cash equal to the in-the-money value based on the $65.60 closing amount, plus CVRs per underlying share. Unvested awards maintain vesting terms, with merger-related vesting described to occur by the first anniversary, subject to continued service.
Metsera, Inc. (MTSR) reported insider transactions on Form 4 tied to its merger closing with Pfizer on 11/13/2025. At the effective time, each issued and outstanding Metsera common share was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable upon specified milestones.
The filing lists holdings associated with Population Health Partners: 12,639,787 shares recorded by Population Health Partners, L.P. and 127,675 shares recorded by Population Health Partners GP, LLC. Following the reported transaction, the filing shows 0 shares beneficially owned by the reporting person.
Metsera (MTSR) reported insider transactions tied to its merger with Pfizer effective on 11/13/2025. At closing, each share of Metsera common stock converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon achievement of specified milestones.
Equity awards were also settled under the merger terms. Outstanding stock options were canceled for a cash payment equal to the excess of $65.60 over the exercise price, multiplied by the number of underlying shares, plus one CVR per underlying share; unvested awards follow their schedule but fully vest on the first anniversary of closing, subject to continued service. RSUs were canceled for cash equal to $65.60 per underlying share plus the same number of CVRs, with no vesting conditions on those payments. The filing reflects director Kristina M. Burow’s positions, including indirect interests disclosed through ARCH Venture funds.
Metsera, Inc. (MTSR): Validae Health, L.P. filed a Form 4 reporting a Code J transaction involving the distribution of 12,767,462 shares of Metsera common stock at $0 on November 11, 2025. Following the transaction, the filer reported 0 shares directly owned.
Footnotes state Validae distributed 99% of its Metsera shares to Population Health Partners, L.P. and 1% to Population Health Partners GP, LLC. PHP GP LLC may be deemed to beneficially own shares held by Validae and PHP LP; certain individuals are members of PHP GP LLC and may share dispositive and voting power, with beneficial ownership disclaimed except to the extent of pecuniary interest.
Metsera (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer. At closing, each share of Metsera common stock converted into the right to receive $65.60 in cash per share plus one contingent value right (CVR), per the merger terms.
The reporting person recorded an acquisition of 2,688 RSUs on November 12, 2025, which were then canceled and converted into cash at the Closing Amount and an equal number of CVRs. Outstanding stock options were canceled in exchange for cash equal to intrinsic value and one CVR per underlying share; unvested awards follow prior schedules with vesting on the first merger anniversary subject to continued service. Following these transactions, the Form 4 shows 0 shares of common stock beneficially owned.
Metsera, Inc. (MTSR) filed a Form 4 reflecting transactions tied to its merger with Pfizer Inc.. At the merger’s Effective Time, each share of Metsera common stock was converted into the right to receive $65.60 in cash per share, plus one contingent value right (CVR) payable in cash upon specified milestones.
The reporting person’s holdings changed accordingly: 2,688 shares of common stock were disposed, leaving 0 shares beneficially owned. A restricted stock unit grant of 2,688 RSUs was reported; under the merger, RSUs were canceled and converted into cash equal to the cash amount per share times the RSU count and CVRs equal to the underlying shares, with these payments not subject to vesting. A stock option for 47,730 shares at $19.81 was canceled and exchanged for cash based on the excess of the cash amount over the exercise price, plus one CVR per underlying share. For unvested options, the cash and CVRs will vest on the first anniversary of closing, contingent on continued service.